Literature DB >> 8683323

Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma.

P Magnani1, G Paganelli, G Modorati, F Zito, C Songini, F Sudati, P Koch, H R Maecke, R Brancato, A G Siccardi, F Fazio.   

Abstract

UNLABELLED: SPECT radioimmunoscintigraphy with 99mTc-labeled anti-melanoma monoclonal antibodies (MAbs) 225.28S is being used to detect uveal melanoma. Recently, pretargeting methods have been described to reduce background activity and perform imaging in a shorter time interval.
METHODS: We compared the three-step pretargeting method with conventional radioimmunoscintigraphy in 15 patients with a clinical and laboratory diagnosis of uveal lesion. High-resolution SPECT radioimmunoscintigraphy was performed in all patients with directly labeled MAbs and, 1 wk later, with the three-step pretargeting technique. Eleven patients underwent eye enucleation and specimens of uveal melanoma were available for histology, whereas four patients underwent conservative therapy. The percent injected dose (%ID) delivered to the tumor and the tumor-to-background ratio were calculated.
RESULTS: In all three-step radioimmunoscintigraphy studies, there was a reduction of nonspecific nasopharyngeal background. The three-step radioimmunoscintigraphy tumor-to-nontumor ratio was 3.1 +/- 1.3 versus 1.5 +/- 0.5 of conventional radioimmunoscintigraphy, while the percent injected dose on the tumor was similar for the two methods (4.4 +/- 3.0 versus 3.8 +/- 2.8) x 10(-3).
CONCLUSION: Improved SPECT imaging with the three-step radioimmunoscintigraphy results from reduced background and from higher counting statistics due to reduction of time interval between radiotracer administration and imaging, whereas the absolute amount of tracer delivered to the tumor by the two methods is comparable.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683323

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

1.  Preparation of (111)In-DTPA morpholino oligomer for low abdominal accumulation.

Authors:  Guozheng Liu; Shuping Dou; Mary Rusckowski; Dale Greiner; Donald Hnatowich
Journal:  Appl Radiat Isot       Date:  2010-03-06       Impact factor: 1.513

2.  Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).

Authors:  Nicoletta Urbano; Stefano Papi; Mauro Ginanneschi; Rita De Santis; Silvia Pace; Ragnar Lindstedt; Liliana Ferrari; Sunju Choi; Giovanni Paganelli; Marco Chinol
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-06       Impact factor: 9.236

3.  Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody.

Authors:  Guozheng Liu; Shuping Dou; Ali Akalin; Mary Rusckowski; Philip R Streeter; Leonard D Shultz; Dale L Greiner
Journal:  Nucl Med Biol       Date:  2012-02-10       Impact factor: 2.408

4.  A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.

Authors:  Guozheng Liu; Shuping Dou; Stephen Baker; Ali Akalin; Dengfeng Cheng; Ling Chen; Mary Rusckowski; Donald J Hnatowich
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

5.  Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.

Authors:  Gui-Ping Li; Hui Zhang; Cheng-Mo Zhu; Jian Zhang; Xu-Feng Jiang
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

6.  Human islet cell MORF/cMORF pretargeting in a xenogeneic murine transplant model.

Authors:  Guozheng Liu; Shuping Dou; Dengfeng Cheng; Jean Leif; Mary Rusckowski; Philip R Streeter; Leonard D Shultz; Donald J Hnatowich; Dale L Greiner
Journal:  Mol Pharm       Date:  2011-04-21       Impact factor: 4.939

7.  Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes.

Authors:  Geralda A F van Tilborg; Willem J M Mulder; Daisy W J van der Schaft; Chris P M Reutelingsperger; Arjan W Griffioen; Gustav J Strijkers; Klaas Nicolay
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

8.  Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.

Authors:  Guozheng Liu; Dengfeng Cheng; Shuping Dou; Xiangji Chen; Minmin Liang; P Hendrik Pretorius; Mary Rusckowski; Donald J Hnatowich
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

9.  An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector.

Authors:  Guozheng Liu; Shuping Dou; Mary Rusckowski; Donald J Hnatowich
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

Review 10.  A semiempirical model of tumor pretargeting.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2008-11-19       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.